Compare · LLY vs NATR
LLY vs NATR
Side-by-side comparison of Eli Lilly and Company (LLY) and Nature's Sunshine Products Inc. (NATR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and NATR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.14T, about 5128.3x NATR ($221.9M).
- Over the past year, LLY is up 54.2% and NATR is down 10.6% - LLY leads by 64.7 points.
- LLY has hit the wire 25 times in the past 4 weeks while NATR has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 5 for NATR).
- Company
- Eli Lilly and Company
- Nature's Sunshine Products Inc.
- Price
- $1262.93+0.90%
- $12.80+1.27%
- Market cap
- $1.14T
- $221.9M
- 1M return
- +9.59%
- -2.51%
- 1Y return
- +54.19%
- -10.55%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 25
- 0
- Recent ratings
- 25
- 5
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Nature's Sunshine Products Inc.
Nature's Sunshine Products, Inc., a natural health and wellness company, primarily manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. It also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. The company offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is based in Lehi, Utah.
Latest LLY
- Lilly confirms date and conference call for third-quarter 2026 financial results announcement
- New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
- Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow Builds
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
- SEC Form 3 filed by Eli Lilly and Company
- Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
- Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
- Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Latest NATR
- EVP, Chief Financial Officer Perkins Ruth Ann was granted 75,433 shares (SEC Form 4)
- SEC Form 3 filed by new insider Perkins Ruth Ann
- SVP, Chief Accounting Officer Lanoy Jonathan David was granted 7,210 shares, increasing direct ownership by 15% to 55,602 units (SEC Form 4)
- Large owner Prescott Group Capital Management, L.L.C. bought $293,800 worth of shares (20,000 units at $14.69) (SEC Form 4)
- Large owner Prescott Group Capital Management, L.L.C. bought $2,318,912 worth of shares (141,389 units at $16.40) (SEC Form 4)
- SEC Form 10-Q filed by Nature's Sunshine Products Inc.
- Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- Nature's Sunshine Reports Second Quarter 2026 Results
- Nature's Sunshine Appoints Ruth Perkins as Executive Vice President and Chief Financial Officer
- Nature’s Sunshine Appoints Janine Weber as Executive Vice President and President, North America